
Effective first-line option for cow’s milk allergy that has proven clinical benefits beyond symptom relief
Effective first-line option for cow’s milk allergy that has proven clinical benefits beyond symptom relief
Cow’s milk allergy (CMA) is the most common food allergy in childhood with an estimated annual prevalence of 2–7.5% in infants.1 Guidelines for managing bottle-fed infants with CMA recommend the use of substitutive hypo-allergenic formulas.1,2 Clinical guidelines recommend extensively hydrolysed formula (eHF) first-line for mild-to-moderate CMA which is suitable in 90% of infants.2,3
The clinical benefits of probiotics are dependant on strain specificity.4 The unique combination of extensively hydrolysed casein formula (eHCF) and Lactobacillus rhamnosus GG (LGG®) probiotic in Nutramigen with LGG® modifies the gut microbiome which can provide clinical benefits in the short, medium and long term.4‑9
Nutramigen with LGG®: Proven efficacy at every step*5
*For the dietary management of cow’s milk allergy
Fast effective relief

Nutramigen with LGG® provides rapid and effective relief from CMA symptoms in the short term6,7,8
- Nutramigen with LGG® provides relief from colic due to CMA in 90% of infants and this is often within 48 hours of use.†6
- A study showed significantly reduced gut inflammation (P=0.02) with 0% occult blood in stools, after 4 weeks.7
- Infants receiving Nutramigen with LGG® showed reduced severity of eczema after 4 weeks of use.8
- of parents were satisfied with Nutramigen with LGG®10
- proven average clinical efficacy11
Faster tolerance to milk

Nutramigen with LGG® accelerated return to cow’s milk‡5
Nutramigen with LGG® not only provides fast and effective symptom relief, but also accelerates return to milk (oral tolerance acquisition).
Studies have clinically proven that Nutramigen with LGG® resulted in faster return to milk than other formulas‡ resulting in ~80% of infants returning to cow’s milk after 12 months of use.4,5
A faster return to cow’s milk could also provide cost effectiveness to the NHS.12
Learn more about how Nutramigen with LGG® could provide the NHS with a cost-effective strategy
Reduction in future allergic manifestations

Nutramigen with LGG® reduced the incidence of future allergic manifestations9
Children with CMA have an increased risk of developing allergic manifestation such as eczema, asthma, urticaria or rhinoconjunctivitis.9
A study found that infants using Nutramigen with LGG® compared to eHCF alone reduced the incidence of 1 or more allergic manifestations by ~50% during a 3 year period.9
Reducing the incidence of future allergic manifestations can improve patient outcomes and reduce the NHS cost of patient management.12
See how Nutramigen with LGG® can be the dominant strategy for the dietary management of CMA
Nutramigen with LGG® reduction in incidence
- rhinoconjunctivitis68%
- allergic urticaria61%
- asthma51%
- eczema44%
The unique formula of Nutramigen with LGG® provides rapid symptomatic relief, allowing infants with CMA the ability to enjoy cow’s milk sooner than other formulas with reduced likelihood of developing future allergic manifestations by ~50%.4‑9

Consider recommending Nutramigen with LGG®: clinically proven to offer more than just symptom relief.